U.S. Markets closed

GW Pharmaceuticals plc (GWPH)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
103.04-0.77 (-0.74%)
At close: 4:00PM EDT

103.49 0.45 (0.44%)
After hours: 5:27PM EDT

People also watch
  • Ronnie is just a 13 year old boy wanting your comments. I know him. he is almost a girl.needs a little attention
  • Ronnie, I don't feel like looking through all your posts on here but could you explain to all of us again why you are so against this stock?
  • What's down with the $4 swing today?
  • 150/share...here we come...
  • I remain an optimist. Easily another 30% growth in this stock?
  • You know you have the best company in its industry when everyone and their mother comes to our message board.
  • Check potn
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Is there something I'm missing? The stock trades down day after day. With all they have in the pipeline, established in other countries and waiting on our corrupt country to approve their epilepsy drug. There's something I'm not getting. Shorts like Ronnie and Stevens comments don't count
  • GWPH will prevail Charlotte's Web hasn't gone through the FDA actual studies with data don't lie and once gwph gets it passed you can bet they going to create laws or stop people who did not have studies done from selling a non FDA approved product plus they have orphan drug status so they can shut people down who are selling it and not licensed by them without a court process.
  • Zhou noted, "We see Zynerba as an excellent value play versus GW Pharma, with a differentiated mode of delivery (transdermal vs. oral) and same active ingredient - CBD (cannabidiol). ZYN002 has a better safety and bioavailability profile, and is a synthetic (vs. plant based), which translates into higher margin and better quality control. Zynerba is also targeting a much larger indication in epilepsy vs. orphan drug indications for GW Pharma."

    Furthermore, "We view Zynerba's product candidates as de-risked therapeutic alternatives to GW Pharma, based on the validation of CBD in epilepsy (both safety, efficacy and regulatory pathway), as demonstrated by GW Pharma’s Epidiolex in Dravet syndrome (DS) and Lennox-Gastaut sydrome (LGS) in three phase III trials."
  • food for thought, GW will have tough time in merica with the like in INSY and ZYNE
  • Down again today? What the heck. I suppose now some of you G(one)W(ishing) holders regret now selling when it was over $100.
  • $96 is the new $100. Please sell and at least get that much. Let's be "frank" about it. She is not going to get US approvals anytime soon....if at all
  • Is Hilary Kramer still pumping this stock?
  • Once your out of the stock there is no need to post on its message boards. The only reason is if your shorting the stock and we have a few on here.
  • Bough at 76 sold at 111, bought back in at 85 sold at 100, waiting to go back down to 85 and i will buy again.
  • What's amusing frank is your stubbornness to own this stock
  • I won't buy back in until $82.